REGN vs WEYS · P/E 14, rev $14.34B vs P/E 15, rev $290.3M
Regeneron Pharmaceuticals Inc (REGN) versus Weyco Group Inc (WEYS) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Weyco Group Inc (WEYS) is a footwear & accessories company listed on NASDAQ.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported WEYS revenue for 2024-12-31 was $290.3M. Net income was $30.3M. Revenue was down 8.7% from 2023-12-31 to 2024-12-31. WEYS currently screens at market cap $344.4M and trailing P/E 14.6.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. WEYS currently screens at market cap $344.4M and trailing P/E 14.6.
Not investment advice. Open the REGN and WEYS stock pages for the full models.
Not investment advice.